Literature DB >> 11746631

Neuroleptic malignant syndrome in advanced Parkinson's disease.

P H Gordon1, S J Frucht.   

Abstract

Neuroleptic malignant syndrome is a serious complication of levodopa withdrawal in patients with Parkinson's disease. We report a patient with advanced parkinsonism who developed neuroleptic malignant syndrome in the setting of inadequate levodopa intake. His symptoms improved with levodopa replacement, but dramatically worsened when enteral feeding was begun due to interference with intestinal absorption of levodopa. Copyright 2001 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11746631     DOI: 10.1002/mds.1166

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  5 in total

Review 1.  Parkinsonism-Hyperpyrexia Syndrome and Dyskinesia-Hyperpyrexia Syndrome in Parkinson's Disease: Two Cases and Literature Review.

Authors:  Jian-Yong Wang; Jie-Fan Huang; Shi-Guo Zhu; Shi-Shi Huang; Rong-Pei Liu; Bei-Lei Hu; Jian-Hong Zhu; Xiong Zhang
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 2.  The parkinsonism-hyperpyrexia syndrome.

Authors:  Edward J Newman; Donald G Grosset; Peter G E Kennedy
Journal:  Neurocrit Care       Date:  2008-08-20       Impact factor: 3.210

Review 3.  Dyskinesia-hyperpyrexia syndrome in Parkinson's disease: a systematic review.

Authors:  Miao Wang; Wei Wang; Zhongbao Gao; Xi Yin; Tong Chen; Ziying Jiang; Zhenfu Wang
Journal:  Clin Auton Res       Date:  2021-04-07       Impact factor: 4.435

4.  Malignant syndrome in Parkinson's disease without dopaminergic drug withdrawal.

Authors:  C J Suresh Chandran
Journal:  Ann Indian Acad Neurol       Date:  2008-10       Impact factor: 1.383

Review 5.  Implications of dopaminergic medication withdrawal in Parkinson's disease.

Authors:  J Koschel; K Ray Chaudhuri; L Tönges; M Thiel; V Raeder; W H Jost
Journal:  J Neural Transm (Vienna)       Date:  2021-07-29       Impact factor: 3.850

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.